Study of a c-MET drug for advanced solid tumors
Part of Cancer clinical trials.
This Phase 2 trial tests whether a c-MET inhibitor can slow or shrink advanced solid tumors that have specific c-MET genetic changes. You may be eligible if your cancer has progressed after standard treatment and you meet safety and heart/health requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 19 years old and can give informed consent
- Your advanced solid tumor has a confirmed c-MET change from tumor testing (NGS and/or other required lab confirmation), and it is not NSCLC with c-MET exon 14 skipping
- Your cancer has gotten worse after standard treatment, or there is no standard treatment option for you
- You have at least one measurable or evaluable tumor spot on scans, and your body function tests are strong enough (blood counts, liver, kidneys)
- You can eat, you’re expected to live at least 90 days, and your heart rhythm test (QTcF) is within the allowed range
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, GSK5533524, alone or with other treatments, for people with advanced solid tumors that have stopped responding to standard therapies. It aims to find out if the drug is safe and shows early signs of working.
This Phase 2 study tests ABN401 to see how well it works and how safe it is for people with advanced non-small cell lung cancer (NSCLC) that has certain c-MET (a protein) changes. It may help some tumors that have not responded well to prior treatment, especially certain EGFR-related cases.
This trial tests a new drug called CKD-703 for people with advanced solid tumors, including a type of lung cancer (non-small cell lung cancer) that has a specific marker called c-Met. The study aims to see if the drug is safe and effective for those who have already tried other treatments that didn't work or caused side effects.
This trial tests a new drug (ANS014004) for people with advanced solid tumors that have a specific gene change (MET, ROS1, or NTRK). It aims to see if the drug is safe and can shrink tumors.
This trial tests a new drug, VERT-002, for people with advanced solid tumors, including non-small cell lung cancer (NSCLC), that have specific changes in the MET gene. It aims to see if the drug can shrink tumors or stop them from growing when other treatments haven't worked or aren't available.
This trial tests a drug called telisotuzumab adizutecan for people whose cancer has a specific genetic change called MET amplification. It may help when standard treatments are no longer working.
Hear when a new Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.